Walleye Capital LLC Sells 63,617 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Walleye Capital LLC trimmed its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 50.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,980 shares of the company's stock after selling 63,617 shares during the period. Walleye Capital LLC owned 0.12% of Tyra Biosciences worth $875,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Rhumbline Advisers raised its position in shares of Tyra Biosciences by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock valued at $364,000 after acquiring an additional 1,027 shares during the last quarter. Barclays PLC lifted its stake in Tyra Biosciences by 200.5% in the third quarter. Barclays PLC now owns 37,625 shares of the company's stock valued at $884,000 after buying an additional 25,106 shares during the period. JPMorgan Chase & Co. lifted its stake in Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after buying an additional 3,896 shares during the period. Franklin Resources Inc. bought a new position in Tyra Biosciences during the third quarter worth about $278,000. Finally, State Street Corp grew its position in shares of Tyra Biosciences by 4.4% during the 3rd quarter. State Street Corp now owns 384,732 shares of the company's stock worth $9,045,000 after buying an additional 16,248 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Tyra Biosciences news, Director Nina S. Kjellson sold 5,401 shares of the company's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the sale, the director now directly owns 443,885 shares of the company's stock, valued at approximately $6,107,857.60. This represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 15.40% of the stock is currently owned by corporate insiders.

Tyra Biosciences Stock Performance

NASDAQ TYRA traded down $0.05 on Friday, reaching $10.04. The company had a trading volume of 101,051 shares, compared to its average volume of 251,175. The company's fifty day moving average is $10.03 and its 200-day moving average is $14.21. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60. The firm has a market capitalization of $533.02 million, a price-to-earnings ratio of -6.24 and a beta of 1.19.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. On average, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on TYRA. Wedbush reissued an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. UBS Group assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.